Dr. Michael W. Meshad, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (1972)
- Years since graduation
- 54
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 468
Licensed in Alabama since 1975, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1972Medical school: University of Alabama School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
AL license 7158 (first issued 1975; active) -
Hematology & Oncology Physician
AL license 7158 (first issued 1975; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mobile Infirmary Medical Center Mobile, AL
- Thomas Hospital Fairhope, AL
- USA Health HCA Providence Hospital, LLC Mobile, AL
- Springhill Medical Center Mobile, AL
- North Baldwin Infirmary Bay Minette, AL
Medical groups
- Southern Cancer Center PC (25 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 468
- Services billed
- 104,370
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 21,400 | 19 |
| Injection, fosaprepitant, 1 mg | 9,300 | 19 |
| Injection, denosumab, 1 mg | 3,900 | 21 |
| Injection, dexamethasone sodium phosphate, 1 mg | 900 | 29 |
| Injection, palonosetron hcl, 25 mcg | 760 | 19 |
| Insertion of needle into vein for collection of blood sample | 746 | 220 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 716 | 216 |
| Injection, ondansetron hydrochloride, per 1 mg | 656 | 17 |
| Blood test, comprehensive group of blood chemicals | 597 | 211 |
| Established patient office or other outpatient visit, 20-29 minutes | 426 | 223 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Mobile, AL | 214 |
| Anastrozole Other prescribers in Mobile, AL | 89 |
| Prednisone Other prescribers in Mobile, AL | 55 |
| Hydroxyurea Other prescribers in Mobile, AL | 54 |
| Brukinsa (zanubrutinib) | 54 |
| Abiraterone Acetate | 53 |
| Ondansetron Hcl Other prescribers in Mobile, AL | 50 |
| Dexamethasone Other prescribers in Mobile, AL | 39 |
| Trazodone Hcl Other prescribers in Mobile, AL | 38 |
| Calquence (acalabrutinib maleate) | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 34 companies reported 108 payments worth $2,150 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $337 |
|---|---|
| Celgene Corporation | $169 |
| Janssen Biotech, Inc. | $155 |
| Merck Sharp & Dohme LLC | $133 |
| Eisai Inc. | $103 |
| Springworks Therapeutics, Inc. | $102 |
| GlaxoSmithKline, LLC. | $91.43 |
| Pfizer Inc. | $82.17 |
| Food and Beverage | $2,150 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 30 industry-funded studies in 2025, from 14 companies. The companies reported $1,233,354 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherap…
AstraZeneca Pharmaceuticals LP - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Daiichi Sankyo Inc. · Active, not recruiting · NCT05555732 - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340 - Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc. - Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-lin…
E.r. Squibb & Sons, L.l.c. - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - ALI-4201
Puma Biotechnology, Inc. - A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in…
AstraZeneca Pharmaceuticals LP - A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Epizyme, Inc. · Active, not recruiting · NCT04224493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.